Methylene blue administration in refractory distributive shock

Download PDF Česká verzia

Authors: M. Pořízka ¹; H. Říha ^1,2; M. Balík ¹
Authors place of work: Klinika anesteziologie, resuscitace a intenzivní medicíny, 1. lékařská fakulta Univerzity Karlovy, a Všeobecná fakultní nemocnice, Praha ¹; Klinika anesteziologie a resuscitace, Kardiocentrum, Institut klinické a experimentální medicíny, Praha ²
Published in the journal: Anest. intenziv. Med., 32, 2021, č. 4-5, s. 211-216
Category: Review Article

Summary

Refractory distributive shock is associated with excessive mortality in critically ill patients. Non-adrenergic vasopressors, including methylene blue, are often considered as an adjuvant therapy to the usual, catecholamine-based vasopressor treatment. In this narrative review we summarize the current scientific evidence on the use of methylene blue in the treatment of refractory distributive shock in different clinical situations.

Keywords:

ene blue – distributive shock – refractory shock – vasoplegia – vascular hyporesponsiveness

Zdroje

Bassi E, Park M, Azevedo LC. Therapeutic strategies for high‑dose vasopressor‑dependent shock. Crit Care Res Pract. 2013; 2013: 654708. doi: 10.1155/2013/654708.
De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, et al.; SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010; 362(9): 779–789. doi: 10.1056/NEJMoa0907118.
Jenkins CR, Gomersall CD, Leung P, Joynt GM. Outcome of patients receiving high dose vasopressor therapy: a retrospective cohort study. Anaesth Intensive Care. 2009; 37(2): 286–289.
Levy B, Collin S, Sennoun N, Ducrocq N, Kimmoun A, Asfar P, et al. Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside. Intensive Care Med. 2010 Dec; 36(12): 2019–2029. doi: 10.1007/s00134-010-2045-8.
Russell JA, Gordon AC, Williams MD, Boyd JH, Walley KR, Kissoon N. Vasopressor Therapy in the Intensive Care Unit. Semin Respir Crit Care Med. 2021 Feb; 42(1): 59–77. doi: 10.1055/s-0040-1710320.
Jang DH, Nelson LS, Hoffman RS. Methylene blue for distributive shock: a potential new use of an old antidote. J Med Toxicol. 2013; 9(3): 242–249. doi: 10.1007/s13181-013-0298-7.
Forstermann U, Sessa W. Nitric oxide synthases: regulation and function. Eur Heart J. 2012; 33(829–837): 837a–837d.
Elbers P, Ince C. Mechanisms of critical illness - classifying microcirculatory flow abnormalities in distributive shock. Crit Care. 2006; 10(4): 221.
Cauwels A. Nitric oxide in shock. Kidney Int. 2007; 72: 557–565.
Lambden S, Creagh‑Brown BC, Hunt J, Summers C, Forni LG. Definitions and Pathophysiology of vasoplegic shock. Crit Care. 2018; 22(1): 174.
MacNaul KL, Hutchinson NI. Differential expression of iNOS and cNOS mRNA in human vascular smooth muscle cells and endothelial cells under normal and inflammatory conditions. Biochem Biophys Res Commun. 1993; 196(3): 1330–1334.
Losada AP, Bermúdez R, Faílde LD, Quiroga MI. Quantitative and qualitative evaluation of iNOS expression in turbot (Psetta maxima) infected with Enteromyxum scophthalmi. Fish Shellfish Immunol. 2012; 32(2): 243–248. doi: 10.1016/j.fsi.2011. 11. 007.
Juřica J. Methylenová modř. Remedia. 2018; 28: 264–271.
Lenglet S, Mach F, Montecucco F. Methylene blue: potential use of an antique molecule in vasoplegic syndrome during cardiac surgery. Expert Rev Cardiovasc Ther. 2011 Dec; 9(12): 1519–1525. doi: 10.1586/erc.11.160.
Clifton J, Leikin JB. Methylene blue. Am J Ther. 2003; 10(4): 289–291.
Tchen S, Sullivan JB. Clinical utility of midodrine and methylene blue as catecholamine‑sparing agents in intensive care unit patients with shock. J Crit Care. 2020 Jun; 57: 148–156. doi: 10.1016/j.jcrc.2020. 02. 011.
Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017 Mar; 43(3): 304–377. doi: 10.1007/s00134-017-4683-6.
Peng Q, Brown SB, Moan J, Nesland JM, Wainwright M, Griffiths J, et al. Biodistribution of a methylene blue derivative in tumor and normal tissues of rats. J Photochem Photobiol B. 1993 Sep; 20(1): 63–71. doi: 10.1016/1011-1344(93)80132-s.
Watson D, Grover R, Anzueto A, Lorente J, Smithies M, Bellomo R, et al. Glaxo Wellcome International Septic Shock Study Group. Cardiovascular effects of the nitric oxide synthase inhibitor NG‑methyl‑L-arginine hydrochloride (546C88) in patients with septic shock: results of a randomized, double‑blind, placebo‑controlled multicenter study (study no. 144-002). Crit Care Med. 2004 Jan; 32(1): 13–20. doi: 10.1097/01.CCM.0000104209.07273.FC.
Gachot B, Bedos JP, Veber B, Wolff M, Regnier B. Short‑term effects of methylene blue on hemodynamics and gas exchange in humans with septic shock. Intensive Care Med. 1995; 21(12): 1027–1031. https://doi.org/10.1007/bf01700666.
Park BK, Shim TS, Lim CM, Lee SD, Kim WS, Kim DS, et al. The effects of methylene blue on hemodynamic parameters and cytokine levels in refractory septic shock. Korean J Intern Med. 2005; 20(2): 123–128. doi: 10.3904/kjim.2005. 20. 2.123.
Memis D, Karamanlioglu B, Yuksel M, Gemlik I, Pamukcu Z. The influence of methylene blue infusion on cytokine levels during severe sepsis. Anaesth Intensive Care. 2002; 30(6): 755–762. doi: 10.1177/0310057X0203000606.
Kirov MY, Evgenov OV, Evgenov NV, Egorina EM, Sovershaev MA, Sveinbjørnsson B, et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med. 2001 Oct; 29(10): 1860–1867. doi: 10.1097/00003246-200110000-00002. PMID: 11588440.
Ramamoorthy S, Patel S, Bradburn E, Kadry Z, Uemura T, Janicki P, et al. Use of methylene blue for treatment of severe sepsis in an immunosuppressed patient after liver transplantation. Case Rep Transplant. 2013; 2013: 203791. doi: 10.1155/2013/203791.
Denny JT, Burr AT, Balzer F, Tse JT, Denny JE, Chyu D. Methylene blue treatment for cytokine release syndrome‑associated vasoplegia following a renal transplant with rATG infusion: A case report and literature review. Exp Ther Med. 2015 May; 9(5): 1915–1920. doi: 10.3892/etm.2015.2349.
Heemskerk S, van Haren FM, Foudraine NA, Peters WH, van der Hoeven JG, Russel FG, et al. Short‑term beneficial effects of methylene blue on kidney damage in septic shock patients. Intensive Care Med. 2008 Feb; 34(2): 350–354. doi: 10.1007/s00134-007-0867-9.
Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol. 1996; 271(5 Pt 1): C1424–C1437. doi: 10.1152/ajpcell. 1996.271. 5. C1424.
Blackwell TS, Christman JW. Sepsis and cytokines: current status. Br J Anesth. 1996; 77: 110–117.
Harbrech BG, Wang SC, Simmons RL, Billiar TR. Cyclic GMP and guanylate cyclase mediate lipopolysaccharide‑induced Kupffer cell tumor necrosis factor‑α sysnthesis. J Leukoc Biol. 1995; 57: 297–302.
Lieberman P. The use of antihistamines in the prevention and treatment of anaphylaxis and anaphylactoid reactions. J Allergy Clin Immunol. 1990; 86(4 Pt 2): 684–686. doi: 10.1016/s0091-6749(05)80241-6.
Enjeti S, Bleecker ER, Smith PL, Rabson J, Permutt S, Traystman RJ. Hemodynamic mechanisms in anaphylaxis. Circ Shock. 1983; 11(4): 297–309.
Tanimoto A, Wang KY, Murata Y, Kimura S, Nomaguchi M, Nakata S, et al. Histamine upregulates the expression of inducible nitric oxide synthase in human intimal smooth muscle cells via histamine H1 receptor and NF‑kappaB signaling pathway. Arterioscler Thromb Vasc Biol. 2007; 27(7): 1556–1561. doi: 10.1161/ATVBAHA.106.139089.
Li H, Burkhardt C, Heinrich UR, Brausch I, Xia N, Förstermann U. Histamine upregulates gene expression of endothelial nitric oxide synthase in human vascular endothelial cells. Circulation. 2003; 107(18): 2348–2354. doi: 10.1161/01.CIR.0000066697.19571.AF.
Oliveira Neto AM, Duarte NM, Vicente WV, Viaro F, Evora PR. Methylene blue: an effective treatment for contrast medium‑induced anaphylaxis. Med Sci Monit. 2003 Nov; 9(11): CS102–6.
Del Duca D, Sheth SS, Clarke AE, Lachapelle KJ, Ergina PL. Use of methylene blue for catecholamine‑refractory vasoplegia from protamine and aprotinin. Ann Thorac Surg. 2009 Feb; 87(2): 640–642. doi: 10.1016/j.athoracsur.2008. 07. 017.
Rodrigues JM, Pazin Filho A, Rodrigues AJ, Vicente WV, Evora PR. Methylene blue for clinical anaphylaxis treatment: a case report. Sao Paulo Med J. 2007 Jan 4; 125(1): 60–62. doi: 10.1590/s1516-31802007000100012.
Laes JR, Williams DM, Cole JB. Improvement in Hemodynamics After Methylene Blue Administration in Drug‑Induced Vasodilatory Shock: A Case Report. J Med Toxicol. 2015 Dec; 11(4): 460–463. doi: 10.1007/s13181-015-0500-1.
Jang DH, Nelson LS, Hoffman RS. Methylene blue in the treatment of refractory shock from an amlodipine overdose. Ann EmergMed. 2011; 58: 565–567.
Lenasi H, Kohlstedt K, Fichtlscherer B, Mülsch A, Busse R, Fleming I. Amlodipine activates the endothelial nitric oxide synthase by altering phosphorylation on Ser1177 and Thr495. Cardiovasc Res. 2003; 59: 844–853.
Hall RI, Smith MS, Rocker G. The systemic inflammatory response to cardiopulmonary bypass: Pathophysiological, therapeutic, and pharmacological considerations. Anesth Analg. 1997; 85: 766–782.
Wan S, LeClerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass: Mechanisms involved and possible therapeutic strategies. Chest. 1997; 112: 676–692.
Kerbaul F, Guidon C, Lejeune PJ, Mollo M, Mesana T, Gouin F. Hyperprocalcitonemia is related to noninfectious postoperative severe systemic inflammatory response syndrome associated with cardiovascular dysfunction after coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2002; 16: 47–53.
Gomes WJ, Carvalho AC, Palma JH, Teles CA, Branco JN, Silas MG, et al. Vasoplegic syndrome after open heart surgery. J Cardiovasc Surg (Torino). 1998; 39: 619–623.
Levin MA, Lin HM, Castillo JG, Adams DH, Reich DL, Fischer GW. Early on‑cardiopulmonary bypass hypotension and other factors associated with vasoplegic syndrome. Circulation. 2009; 120: 1664–1671.
Mets B, Michler RE, Delphin ED, Oz MC, Landry DW. Refractory vasodilation after cardiopulmonary bypass for heart transplantation in recipients on combined amiodarone and angiotensin‑converting enzyme inhibitor therapy: a role for vasopressin administration. J Cardiothorac Vasc Anesth. 1998; 12: 326–329.
Raja SG, Dreyfus GD. Vasoplegic syndrome after off‑pump coronary artery bypass surgery: an unusual complication. Tex Heart Inst J. 2004; 31: 421–424.
Weis F, Kilger E, Beiras‑Fernandez A, Nassau K, Reuter D, Goetz A. Association between vasopressor dependence and early outcome in patients after cardiac surgery. Anaesthesia. 2006; 61: 938–942.
Sundaram V, Fang JC. Gastrointestinal and liver issues in heart failure. Circulation. 2016; 133: 1696–1703.
Yiu P, Robin J, Pattison CW. Reversal of refractory hypotension with single‑dose methylene blue after coronary artery bypass surgery. J Thorac Cardiovasc Surg. 1999; 118: 195–196.
Říha H, Říhová L, Pinďák M, Březina A, Pirk J. Metylénova modř v léčbě vazoplegického syndromu po kardiochirurgické operaci. Čas Lék Česk. 2006; 145: 322–324.
Levin RL, Degrange MA, Bruno GF, Del Mazo CD, Taborda DJ, Griotti JJ, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg. 2004; 77: 496–499.
Maslow AD, Stearns G, Butala P, Schwartz CS, Gough J, Singh AK. The hemodynamic effects of methylene blue when administered at the onset of cardiopulmonary bypass. Anesth Analg. 2006; 103: 2–8.
Ozal E, Kuralay E, Yildirim V, Kilic S, Bolcal C, Kücükarslan N, et al. Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann Thorac Surg. 2005; 79: 1615–1619.
Kofler O, Simbeck M, Pichlmaier M, Zwissler B, Von Dossow V. Treatment of vasoplegic syndrome during cardiopulmonary bypass with methylene blue restores hemodynamic function and affects the overall survival: A 10-years retrospective large‑volume cohort study abstract. Eur J Anaesthesiol. 2018; 35: 188.
Weiner MM, Lin HM, Danforth D, Rao S, Hosseinian L, Fischer GW. Methylene blue is associated with poor outcomes in vasoplegic shock. J Cardiothorac Vasc Anesth. 2013; 27: 1233–1238.
Metz S, Horrow JC, Goel IP, Kuretu ML, Bellwoar C. Methylene blue does not neutralize heparin after cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 1996; 10: 474–476.
de Waal EEC, van Zaane B, van der Schoot MM, Huisman A, Ramjankhan F, van Klei WA, et al. Vasoplegia after implantation of a continuous flow left ventricular assist device: Incidence, outcomes and predictors. BMC Anesthesiol. 2018; 18: 185.
Ortoleva J, Roberts RJ, Devine LT, French A, Kawabori M, Chen F, et al. Methylene blue for vasoplegia during extracorporeal membrane oxygenation support. J Cardiothorac Vasc Anesth. 2020 Dec 29:S1053-0770(20)31389-6. doi: 10.1053/j. jvca.2020. 12. 042.
Říha H, Augoustides JG. Pro: Methylene blue as a rescue therapy for vasoplegia after cardiac surgery. J Cardiothorac Vasc Anesth. 2011; 25: 736–738.
Andritsos MJ. Con: methylene blue should not be used routinely for vasoplegia perioperatively. J Cardiothorac Vasc Anesth. 2011; 25: 739–743.
Pořízka M, Kopecký P, Dvořáková H, Kunstyr J, Lips M, Michalek P, et al. Methylene blue administration in patients with refractory distributive shock – a retrospective study. Sci Rep. 2020; 10: 1828.
Evora PR, Ribeiro PJ, Vicente WV, Reis CL, Rodrigues AJ, Menardi AC, et al. Methylene blue for vasoplegic syndrome treatment in heart surgery: fifteen years of questions, answers, doubts and certainties. Rev Bras Cir Cardiovasc. 2009; 24(3): 279–288. doi: 10.1590/s0102-76382009000400005
Héritier Barras AC,Walder B, SeeckM. Serotonin syndrome following methylene blue infusion: a rare complication of antidepressant therapy. J Neurol Neurosurg Psychiatry. 2010 Dec; 81(12): 1412–1413. doi: 10.1136/jnnp.2009.172221.
Martino EA, Winterton D, Nardelli P, Pasin L, Calabrò MG, Bove T, et al. The Blue Coma: The Role of Methylene Blue in Unexplained Coma After Cardiac Surgery. J Cardiothorac Vasc Anesth. 2016; 30(2): 423–427. doi: 10.1053/j.jvca.2015. 09. 011.
Goluboff N, Wheaton R. Methylene blue‑induced cyanosis and acute hemolytic anemia complicating the treatment of methemoglobinemia. J Pediatr. 1961; 58: 86–89.
Weingartner R, Oliveira E, Oliveira ES, Sant’Anna UL, Oliveira RP, Azambuja LA, et al. Blockade of the action of nitric oxide in human septic shock increases systemic vascular resistance and has detrimental effects on pulmonary function after a short infusion of methylene blue. Braz J Med Biol Res. 1999; 32(12): 1505–1513.
Puntillo F, Giglio M, Pasqualucci A, Brienza N, Paladini A, Varrassi G. Vasopressor‑Sparing Action of Methylene Blue in Severe Sepsis and Shock: A Narrative Review. Adv Ther. 2020 Sep; 37(9): 3692–3706. doi: 10.1007/s12325-020-01422-x.
Kessler MR, Eide T, Humayun B, Poppers PJ. Spurious pulse oximeter desaturation with methylene blue injection. Anesthesiology. 1986; 65(4): 435–436.
Busse LW, Barker N, Petersen C. Vasoplegic syndrome following cardiothoracic surgery–review of pathophysiology and update of treatment options. Crit Care. 2020; 24(1): 36.